• In June 2026, Viking Therapeutics appointed Hubert C. Chen, M.D., as chief medical officer to lead its clinical, medical, and regulatory functions under CEO Brian Lian.
• Dr. Chen’s background in obesity, type 2 diabetes, and regulatory strategy for successful drug approvals directly aligns with Viking’s focus on VK2735 and broader metabolic programs.
• Now we’ll explore how Dr. Chen’s arrival as chief medical officer could shape Viking Therapeutics’ investment narrative around obesity treatments.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

Viking Therapeutics Investment Narrative Recap

To own Viking Therapeutics, you need to believe VK2735 can convert late stage obesity trials into future commercial value despite today’s zero revenue and widening losses. The key near term catalyst is still VANQUISH Phase III data, while the biggest risk remains trial delay, failure, or safety issues that extend substantial cash burn. Dr. Hubert Chen’s appointment does not change those fundamentals, but it may help the company execute against its clinical and regulatory hurdles more effectively.

Among recent updates, the ECO 2026 data for oral VK2735, with up to 12.2% weight loss over 13 weeks and largely mild to moderate side effects, is particularly relevant. These data sit alongside the VANQUISH-1 and VANQUISH-2 Phase III programs and help frame how Dr. Chen’s regulatory and metabolic disease experience could matter most if Viking moves its oral formulation toward Phase III and seeks to align both programs with evolving regulatory expectations.

Yet investors should also be aware that if large Phase III trials require more time, patients, or follow up than expected, the impact on cash needs and future dilution could...

Viking Therapeutics' narrative projects $118.5 million revenue and $12.9 million earnings by 2029. This implies an earnings increase of about $372 million from -$359.6 million today.

Uncover how Viking Therapeutics' forecasts yield a $92.72 fair value, a 205% upside to its current price.

Exploring Other Perspectives

While consensus focuses on execution risk, the most optimistic analysts once modeled about US$497.5 million in revenue and US$62.2 million in earnings by 2029, showing how views on VK2735’s potential and Dr. Chen’s impact can differ widely and may shift as new data and regulatory progress emerge.

Explore 12 other fair value estimates on Viking Therapeutics - why the stock might be worth over 3x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Viking Therapeutics research is our analysis highlighting 2 important warning signs that could impact your investment decision.
• Our free Viking Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viking Therapeutics' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Explore 31 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.